Gamma delta HSTCL post allo relapse HLH active disease CD38 positive - Dara refractory options
Reading File
Searching PubMed
hepatosplenic T-cell lymphoma relapsed refractory treatment
Searching PubMed
gamma delta T-cell lymphoma post-transplant relapse salvage
Searching the Web
gamma delta HSTCL post allo relapse HLH treatment options 2025 2026
Searching PubMed
HLH lymphoma-associated emapalumab ruxolitinib treatment
Searching PubMed
T-cell lymphoma CAR-T CD7 relapsed refractory
Searching PubMed
peripheral T-cell lymphoma daratumumab CD38 resistance salvage bendamustine pralatrexate
Reading Article
PMID: 39874497
Reading Web Page
https://www.hematologyandoncology.net/archives/may-2026/hemo…
Searching PubMed
secondary HLH lymphoma-associated ruxolitinib emapalumab treatment outcomes
Searching PubMed
PTCL relapsed refractory mogamulizumab brentuximab romidepsin duvelisib
Finding Sources
Searching the Web
HSTCL post-transplant relapse targeted therapy clinical trial 2025 STAT5B PI3K CAR-T options
Reading File
Searching PubMed
lymphoma-associated HLH treatment etoposide ruxolitinib anakinra emapalumab
Searching PubMed
HSTCL daratumumab CD38 case report response
Here is a structured, evidence-based analysis of the therapeutic landscape for this scenario. I want to be upfront: this is one of the most treatment-refractory situations in hematologic oncology. There is no randomized data or established standard of care; all options are extrapolated from case reports, small series, and mechanistic rationale.
Gamma-Delta HSTCL - Post-Allo Relapse + HLH + Dara-Refractory: Treatment Options
Framing the Problem
This patient has three simultaneous challenges that must be addressed in parallel:
- Active HSTCL - intrinsically chemorefractory, especially post-allo relapse
- HLH - likely driven by the lymphoma (secondary/macrophage activation syndrome), which will not resolve without controlling the underlying disease
- Dara-refractory CD38+ disease - rules out a CD38-targeted mechanism, eliminates the most validated agent in this entity
The HLH is almost certainly lymphoma-driven (not a separate entity), so effective lymphoma control is HLH control. However, HLH itself causes life-threatening organ dysfunction and requires concurrent specific management.
PART 1: HLH - Immediate Management
The cytokine storm must be addressed right now, even before disease control is achieved.
| Agent | Rationale | Evidence |
|---|---|---|
| Dexamethasone (high-dose, 10 mg/m²) | Cornerstone of all HLH protocols | HLH-94/2004 backbone |
| Etoposide | Macrophage-targeted cytotoxic; also active against underlying T-cell lymphoma | HLH-94 protocol; dual utility here |
| Ruxolitinib (JAK1/2 inhibitor) | Blocks IFN-γ, IL-6, IL-18 signaling driving cytokine storm; case series in secondary HLH; 2025/2026 review supports its use in refractory HLH | Growing case series; REACH trials for GVHD support pleiotropic immunosuppression |
| Emapalumab (anti-IFN-γ) | FDA-approved for primary HLH; increasing compassionate use in refractory secondary HLH; SOBI data 2025 shows 64.7% ORR in primary HLH | Case series; compassionate use pathway |
| Anakinra (IL-1 blocker) | Less evidence in lymphoma-HLH; useful adjunct if IL-1-predominant phenotype | Case series |
| Cyclosporine | Use with caution post-allo; potential GVH benefit but nephrotoxic, immunosuppressive | Standard HLH adjunct |
Key decision: Ruxolitinib + dexamethasone is probably the best bridge while you address the lymphoma, given it also has potential anti-lymphoma activity in STAT-driven T-cell lymphomas. Emapalumab is the escalation option if HLH does not respond.
PART 2: Active HSTCL - Lymphoma-Directed Options (Dara-Refractory)
Given dara-refractoriness, the following categories of agents are worth considering. This is entirely off-label/experimental territory.
A. Approved agents with some T-cell lymphoma activity
| Agent | Rationale | Notes |
|---|---|---|
| Gemcitabine-based (GemOx, GDP) | Platinum/gemcitabine regimens more active in HSTCL than CHOP per Harrison's 2025 - "Cytarabine/etoposide/platinum-based regimens appear more effective than CHOP-based regimens" | Prior exposure likely; may still work for bridging |
| Pralatrexate (Folotyn) | FDA-approved all PTCL subtypes; antifolate with data in rare PTCL including HSTCL (case reports); unique mechanism | Mucositis, thrombocytopenia limiting |
| Romidepsin (HDAC inhibitor) | PTCL-approved; real-world data with duvelisib + romidepsin shows activity in PTCL subtypes [PMID 40526834, 2025] | T-cell lineage active; evaluate organ function |
| Duvelisib (PI3Kδ/γ inhibitor) | PI3K pathway active in T-cell lymphomas; combined with romidepsin shows activity; PI3K-gamma highly expressed in T-cells including HSTCL | [PMID 40526834] multicenter real-world data 2025 |
| Bendamustine | Alkylator with some T-cell lymphoma activity; single agent or combination | Reasonable toleration |
B. Exploiting CD38 beyond daratumumab
Dara-refractoriness can occur via CD38 downregulation, complement inhibition (CD55/CD59 upregulation), or effector cell exhaustion. Options:
| Agent | Mechanism | Notes |
|---|---|---|
| Isatuximab (Sarclisa) | Anti-CD38, different epitope than daratumumab; some activity post-dara in myeloma; no HSTCL data | Worth considering if CD38 still expressed on restaining |
| ADCT-1 / CD38-ADC | Investigational | Clinical trial only |
Check CD38 expression by flow/IHC again - if truly downregulated post-dara, CD38-directed therapy is futile.
C. STAT5B mutation-targeted approach
~30% of HSTCL harbor STAT5B mutations (gain-of-function). If present:
- JAK inhibitors (ruxolitinib, pacritinib, fedratinib) - STAT5B is downstream of JAK2; inhibiting upstream JAK may abrogate proliferative signaling
- This also supports the use of ruxolitinib for dual HLH + lymphoma purposes in this patient
- STAT3/5 direct inhibitors are investigational (no clinical-stage agents yet for HSTCL)
D. Novel/investigational targets
| Target | Agent | Rationale |
|---|---|---|
| CD7 | Anti-CD7 CAR-T | HSTCL is typically CD7+; case reports of CD7 CAR-T bridging to allo in HSTCL [PMID 37667507, 2023]; CD7 CAR-T then allo approach documented |
| NKG2D ligands | NKG2D-CAR or NK cells | γδ T-cells express NKG2D ligands; some NK-cell based approaches |
| PD-1/PD-L1 | Pembrolizumab / nivolumab | Caution post-allo (GVHD risk); some T-cell lymphoma signal but significant immune toxicity risk; not recommended without careful GVH assessment |
| Brentuximab vedotin | If CD30 expressed | HSTCL is typically CD30-; check IHC; not usually applicable |
| Venetoclax | BCL-2 inhibitor | Limited T-cell lymphoma data; case reports in PTCL; BCL-2 can be expressed in HSTCL |
PART 3: Second Allo vs. Alternative Transplant Strategy
Post-allo relapse does NOT automatically preclude a second transplant, but the bar is high:
- Donor lymphocyte infusions (DLI) - if the first allo was from the same donor and no active GVHD; may generate graft-vs-lymphoma effect; safest option to attempt first before full retransplant
- Second allo (different donor / alternative conditioning) - has been performed in HSTCL; only realistic if disease CR/PR is re-achieved; NRM is very high post-second allo
- The PMID 37667507 case used CD7 CAR-T as a bridge to haploidentical second transplant - this is the best-described pathway for HSTCL post-first allo relapse
Recommended Sequencing (Practical Approach)
IMMEDIATE (Days 1-7):
→ Dexamethasone + Etoposide (HLH-2004 backbone, dual lymphoma activity)
→ Add Ruxolitinib for refractory/severe HLH cytokine storm (20 mg BID)
SHORT-TERM (Bridge to disease control):
→ Re-biopsy / reflow to confirm CD38 expression, check STAT5B mutation status, CD7, CD30, PD-L1
→ If CD38 still expressed: consider Isatuximab trial
→ Romidepsin + Duvelisib or GemOx-based regimen for lymphoma control
→ Consider Pralatrexate if renal/cardiac function allows
DISEASE CONTROL ACHIEVED:
→ DLI (if original donor available, no GVHD)
→ Clinical trial enrollment
→ CD7 CAR-T as bridge to second allo (best-supported novel approach)
CLINICAL TRIAL OPTIONS (search clinicaltrials.gov):
→ CD7-targeting constructs (multiple Phase 1/2 trials open)
→ NK cell therapies (CD38+ NK cell platforms)
→ JAK/STAT inhibitor trials in PTCL
Bottom Line
| Priority | Action |
|---|---|
| Most urgent | Control HLH with dex + etoposide + ruxolitinib |
| Key diagnostic step | Re-biopsy for STAT5B mutation, CD7, re-assess CD38 |
| Most promising novel therapy | CD7 CAR-T (case-level evidence in HSTCL specifically) |
| Best salvage chemo option | Romidepsin/duvelisib or platinum-gem backbone |
| Escalation for HLH | Emapalumab if HLH persists despite above |
| Definitive intent | Second allo (if CR achievable) or clinical trial |
The literature on post-allo relapsed HSTCL is almost entirely case reports. This patient needs a tumor board with T-cell lymphoma expertise (e.g., MD Anderson, Stanford, Memorial Sloan Kettering PTCL programs) and urgent clinical trial enrollment review at clinicaltrials.gov for CD7-directed or PTCL-specific trials.
Key references:
- Harrison's Principles of Internal Medicine 22E (2025) - HSTCL management
- Schwartz et al., Blood Advances 2025 (PMID 39874497) - HSTCL review including relapsed disease
- Xu et al., Cell Transplant 2023 (PMID 37667507) - CD7 CAR-T bridge to haplo transplant in HSTCL
- Ford et al., Blood Advances 2025 (PMID 40526834) - Duvelisib + romidepsin real-world PTCL data
- Schaefer et al., Hematology & Oncology May 2026 - HLH targeted therapies including ruxolitinib, emapalumab
This is a shared conversation. Sign in to Orris to start your own chat.